The writer is a long term value investor and M.Sc graduate in Financial Markets with over 10 years experience. Value can be found in both long and short ideas and uses options to enhance the risk-return profile of investment ideas.
Disclaimer: This article provides opinions and information, but does not contain recommendations or personal investment advice to any specific person for any particular purpose. Do your own research or obtain suitable personal advice.
The SA Investor Marketplace is where readers can subscribe to premium research and private communities from top SA authors. Marketplace services cover a wide variety of investment styles, giving readers a chance to invest alongside their favorite authors.
Interested in building a business on Marketplace? Check out this story on authors' success to date, and go here to learn more about writing for SA. Contact us at email@example.com if you'd like to apply to launch a Marketplace service.
Interested in signing up for a Marketplace service? Check out all our authors here. For any questions about SA's Marketplace, contact firstname.lastname@example.org. We'd be happy to hear from you.
This account will be used to highlight these authors and offer insights into investing from the authors to any interested users. Follow this account if you'd like to hear what's going on with the SA Marketplace!
My husband and I each have a DPhil from Oxford University. Mine is in Cell Physiology and his in Bio-Organic Chemistry. He has been working in pharmaceutical research for over 20 years. We invest in companies which have solid science, and avoid those whose science, we estimate, to be weak. We think that biotech companies can fail for many reasons; but none can succeed without solid science.
Disclaimer: My articles are not investment recommendations, and I am not an investment adviser. Though I do my best to obtain information from sources that I regard as reliable, I cannot guarantee their accuracy. Opinions, expressed in my articles, can change with new insight or new information. The disclosure statement is accurate at the time of its publication. However, my personal portfolio can change at any time, without further notice.
Biotech stocks are highly volatile, speculative, and therefore risky. Investing in these stocks may result in a partial or complete loss of investment. Conduct your own due diligence and/or consult a certified financial adviser before making any decision to buy, sell or hold any stock. Remember: readers are responsible for their own investment decisions, actions and results.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
I am passionate about investing since 15 years already... and would like to share a couple of ideas with my readers.
I have an engineering background (PhD) and have worked in the industry bringing billions of dollars of manufacturing facilities up from the ground mainly holding a strategic/commercial role.
Please do your own research and due diligence prior to investing your own money. Good luck!
As a former internal whistle-blower, I sacrificed everything to do the right thing. Markos N. Kaminis generated a 23% average annual return on "Strong Buy" stock selections over 5 years and ranked 2nd among a group of 60 analysts in-house as a Senior Equity Analyst over a seven-year period at Standard & Poor's. After proving his value in-house, he was promoted into a special role as an idea generator, supporting the portfolios of institutional clients as well as driving performance within S&P's recommended lists and portfolios. At times, Markos was responsible for up to 10% of the firm's entire "Strong Buy" list and is due a great deal of credit for the group's outstanding performance during his tenure.
Markos followed a group of 30-40 Small and Mid-Cap firms, and was charged with finding new buy and sell candidates across industry sectors. He generated a 23% average annual return over five years on his "Strong Buy" recommendations, and 26% over three years ended 2004. He was ranked 1st of 60 analysts in-house for his "Strong Buy" performance over 4 years (2nd over 5). Markos also authored IPO research and wrote for high-level newsletters, The Outlook, Equity Insights and Emerging Opportunities, as well as for BusinessWeek Online. He represented his firm as an analytical expert commentator for major media, including television, Internet and through quotes and interviews in reputable publications.
Besides predicting the stock market correction of 2015 through a series of prescient reports here in August. (see proof here: http://seekingalpha.com/article/3482226-investor-who-predicted-the-stock-market-correction-offers-an-update ), Markos also advised investors to buy stocks at the bottom of the market in mid-February 2016 and again post-Brexit at the trough, and to buy gold in January 2016 before the commodity started its move higher. While not perfect, over the years, Markos has made countless correct market and security calls for his followers, including forecasting the demise of J.C. Penney on the heralded CEO hire's disruptive plans, the bankruptcies of Washington Mutual and Pilgrim's Pride in the $30 and $20s, respectively, as well as the purchase of Facebook in the mid-$20s when it was considered a pariah post its IPO (today it is a market darling). Markos also warned of the real estate market collapse and the financial crisis in the early days of his blogging.
What I personally want you to know about my plans: After witnessing the worst of Wall Street firsthand and having the ideal vision of my childhood career choice corrupted by reality, I almost switched to full-time charity work at age 40 and still have plans for several non-profit endeavors. The future is somewhat unknown, and I am open to employment offers for portfolio management or other ideas. While continuing to publish regularly, I expect to begin work on several book ideas that I believe are important for business, for our nation and for society.
I may put my stock selection skills, earned through blood, sweat and tears, to better use, and to make my own way. I would like to give investors something rare, a dignified partner who can manage money with integrity and a clear conscience about the degree of due diligence behind investment decisions... someone who cares more about your money than your wife. I hope readers will become followers of my column here & at my blog, so that when our numbers are substantial, we might start an investment fund or two.
Prior to his Wall Street career, Mr. Kaminis spent time in the back-office, as a mutual fund accountant, where he managed for a time the work of two men. Before this, from age 11 to age 25, he worked as a carpenter's apprentice and carpenter with his father, in both commercial and residential projects. Mr. Kaminis has an intimate knowledge of the real estate (undergraduate degree in Real Estate and Finance) and construction market, as well as the restaurant industry.
However, as a generalist stock analyst, he showed the ability to learn any and the most complicated of industries in short time - and he gamed every challenge presented to him. Mr. Kaminis earned his MBA at the Katz Graduate School of Business at the University of Pittsburgh, and his BA at Temple University in Philadelphia. However, Markos has been studying the stock market since age 13, when he determined his career path.
He made his first investment at age 16, and funded much of his undergraduate education with the proceeds of his investing success. Mr. Kaminis continues to keep busy forecasting the economic path and securities market activity. Markos is considering the eventual start-up a long/short capital appreciation hedge fund. Such a fund would limit risk through beta reduction, using a diversification strategy targeting sector & industry and long & short position inclusion. At the same time, Markos' theoretical fund would seek maximum capital appreciation through the exploitation of Mr. Kaminis' inherent economic & market discernment gift and proven stock selection skills.
Mr. Kaminis also has a team of a select few analysts, technicians, strategists and economists that he has been impressed by over the years, which he expects to tap for the project when the time is right. Mr. Kaminis welcomes your interest in such a potential forward effort, and looks forward to discussing his plans with those appropriate and within legal constraints.
Markos toys with very early stage entrepreneurial efforts in the testing of certain business models, all of which he intends to tie to a planned non-profit project serving the most helpless among us. The tie will be that the businesses will give employment opportunity to individuals who would otherwise have difficulty finding gainful employment. It will house and heal the homeless, ex-convicts, those completing rehabilitation efforts for drug and other addictions, and others in need of help.
Markos is currently Directing the widely syndicated blog he founded, "Wall Street Greek," and is writing for other well-known publications besides advancing several big ideas. Markos' column is syndicated across sites like the Boston Globe, Kiplinger Magazine, UPI and other reputable newspaper and TV websites, as well as private networks, Amazon Kindle, iPhone and more. In the past, he has written for RealMoney.com, Motley Fool and others.
Requests to research specific companies are welcome, as we serve our readers. You may contact us via this blog's contact info. Mr. Kaminis welcomes you to follow him here at Seeking Alpha, where he is proud to be a long-time contributor to this strong team of writers. He considers the Seeking Alpha team and management close friends, and for you, people worth knowing and following. Visit his site: Wall Street Greek (http://www.wallstreetgreek.blogspot.com/)
We are a collaboration of biotechnology insights providing investment research. Currently, we are initiating intermediate/long-term investment coverage on stocks that present with excellent risk-to-reward ratios. We will also occasionally present swing-trade ideas, IPO prospects, deeper looks into biotech stocks on the move, market research, informational-only pieces, technical analysis, etc. At the helm of Clover is Stephen Ayers. He is a Registered Nurse who works on an intermediate care unit in a hospital and witnesses first-hand the powerful impact of medicine. He is an avid biotechnology researcher and advocater. He believes collaboration with persons of differing biotechnology angles will enrich his work. Subsequently, he formed Clover Biotech Research to provide a platform for investors to experience several different perspectives. Clover recently welcomed Gobinath Varadappan, a biomedical engineer with big pharma experience and knowledge of clinical, regulatory, and commercial aspects of drug development. Gobinath is looking forward to making vital contributions to the team. Clover plans to secure additional advisers and writers in the future.
I am currently in my junior year at the University of Southern California, where I am double majoring in business administration and accounting. After completing my degree, I plan to sit for the CPA and work several years in public accounting before assessing my options again. I am very interested in emerging, clinical-stage biotech companies, and specialize in researching and uncovering companies which are undervalued heading into catalyst events. In biotech, every investor will have losers, and sometimes big losers; picking big winners and small losers is key for success in trading this industry. As such, my overall strategy hinges on finding and investing in companies with minimal downside but strong potential upside.
Steven H. Goldman is a commercial litigation lawyer and senior partner in the Toronto law firm of Goldman Hine LLP. Steven graduated with a B.A., President's Medal recipient (1976, Carleton University, Ottawa, Ontario) and J.D. (1980, Queen's University, Kingston, Ontario). He is a former member of the board of directors of Tribute Pharmaceuticals Inc., a Canadian public pharmaceutical company which recently merged with Pozen Pharmaceuticals on February 5, 2016, and now known as Aralez Pharmaceuticals (Nasdaq: ARLZ). Effective May 15, 2018 he was appointed Interim President and CEO of Comstock Metals Ltd. (TSX.V: CSL.V). He is also a member of the board of directors and audit committee of Select Sands Corp. (TSX.Venture: SNS.V and OTCQX: SLSDF). Steven is a member of the Executive of the Ontario Bar Association, Franchise Law Section as well as the American Bar Association, Franchise Forum (Associate Member). Steven was President & CEO of Speedy AutoService and Minute Muffler from December 2007 to December 31, 2009 (with approximately 160 locations across Canada).
President of Almington Capital - Merchant Bankers.
Investing in publicly traded securities, private equity, real estate, venture capital.
Taking advantage of deep value opportunities, growth opportunities, and special situations across a range of asset classes and industries.
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.
Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.
If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research
Disclaimer - we are not investment advisors.
Bespoke Investment Group provides some of the most original content and intuitive thinking on the Street. Founded by Paul Hickey and Justin Walters, formerly of Birinyi Associates and creators of the acclaimed TickerSense blog, Bespoke offers multiple products that allow anyone, from institutions to the most modest investor, to gain the data and knowledge necessary to make intelligent and profitable investment decisions. Along with running their Think B.I.G. finance blog, Bespoke provides timely investment ideas through its Bespoke Premium (http://bespokepremium.com/) subscription service and also manages money (http://bespokepremium.com/mm) for high net worth individuals.
Visit: Bespoke Investment Group (http://bespokeinvest.com/)
I am professional with many years of experience in the pharmaceutical, biotech and device industry covering all functional areas from R&D to product commercialization. I write on Seeking Alpha regarding topics that I find interesting and focus on in depth financial and scientific research.
The Busted IPO Forum founded by Bret Jensen, is a hypothetical $150K portfolio built of stocks that have been public for 18 months to five years that are significantly under their offering price. Many times after the initial analyst hyperbole has died and lockups have expired, these same companies can be had for .30 to .50 cents on the dollar from when the shares went public. As lucrative as this niche has been for Bret's portfolio over the years, a service or newsletter has not existed that covered this segment of the market -- until now! The goal in creating the Busted IPO Forum is to build a portfolio of 15-20 small cap and mid cap busted IPOs which consistently outperform the Russell 2000 over time.
• • •
Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.
• • •
Learn more about Bret Jensen's Marketplace offerings:
The Insiders Forum | The Biotech Forum | Busted IPO Forum
I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com
You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (60,043) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options. I am not afraid to find some biotech stocks to short either after results have proven a drug to be ineffective. Looking at both the negative and positive aspects of biotech investing is the best way to invest in this sector.
Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaboration with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI) marketplace research is delivering robust returns since inception. To name a couple winners, Nektar Therapeutics and Spectrum Pharmaceuticals delivered profits of 446% and 196% for our subscribers, respectively. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios. Of note, we’ll increase our price soon (SUBSCRIBE to IBI now to lock in the current price and save money). Click the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs. To read the FREE once-weekly articles covering promising small-cap bioscience firms, check out www.drtranbiosci.com (and make sure to register for our mailing list). You can read up on Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html "Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
I am a former PhD scientist-turned-writer focused on cancer education. My writings in Seeking Alpha have been devoted to helping people identify promising investment opportunities in cancer research through commentary of recent events. Readers can learn more about other aspects of cancer research by visiting my site Invest Against Cancer.
I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!
Formerly a Wall Street executive from a premier investment bank, author EXP's goal is to help investors discover stocks before the "crowd." The first article published was on "LNG" many years ago; an undiscovered gem. BLOG: https://seekingalpha.com/account/authorboard/instablog
This is not an easy business. Investing is psychological in nature and can be extremely taxing. Patience is key. Not all ideas are written about or picked for publication.
EXP works hard to identify and write about current stock opportunities in the market that can produce some huge gains from disconnects in stock prices. These inefficiencies can be taken advantage of if you can properly identify opportunities, and then manage to act on them before the crowd.
EXP resides in the USA and is very thankful to followers worldwide.
You can also follow EXPstocktrader on: Twitter --- @EXPstocktrader Email --- email@example.com >>>
Disclosure: The administrator(s) of the services mentioned here may be long, short, or flat in any position mentioned as disclosed. All statements are made without any representation to its complete accuracy and administrator(s) are not compensated for posting notes by listed companies. Some minimal compensation is paid by SA if the article gets picked for circulation. EXP never takes money from companies to promote or write about a stock. All stock prices shown are approximate. Ratings may change at any time. All posts are for simulation purposes only. All stock trades transacted by you are at your own risk. We trade stocks and do not usually buy and hold indefinitely. Please take any information that you see here and consult your own investment advisor before making any real trades. EXP, EXPstocktrader and Seeking Alpha are Not licensed to give you investment advice based on your own personal suitability and risk tolerances. Please consult with your financial advisor before making any trades that you read about here or anywhere EXPstocktrader publishes information for that matter. Thank you.
Andrew Left's Citron Research (http://www.citronresearch.com/) (formally known as Stocklemon.com) seeks to expose companies whose management is in some way misleading investors. Left digs into SEC filings, financials, management histories and other data to uncover such situations, and he is usually short the stocks he writes about. Mr. Left has been publishing for 7 years and has created a track record that is unrivaled in short selling. Mr. Left has been cited in Barron's, Wall St Journal, CNBC and other major publications repeatedly for his work. Mr. Left was also an invited speaker at the reknown Master Investor Conference.
Visit: Citron Research (http://www.citronresearch.com/)
We look for potentially undervalued stocks in biotech, technology, and commodities sectors.
We perform research, and give investment opinions and ideas to buy-side firms from time to time.
Make sure to FOLLOW and SUBSCRIBE for the most up to date publications, and access to our chat room.
We are not advisors. Please DM or e-mail firstname.lastname@example.org for idea generation, questions, etc.
Investor/Trader in biotech and tech sectors for 10 years. Founder & Editor of ROTY (Runners of the Year), a strategy and now Marketplace Service focused on discovering opportunities to achieve high % gains within a year´s time frame.
Importantly, I often highlight risk management and entry/exit strategies, as I believe they represent areas that are often neglected but materially important for readers to understand and apply if they want to be profitable long term.
Gaurao is an MBA from Wales university and an engineering graduate from Mumbai university. He is involved in international trade and has been passionately tracking global equity markets for more than 7 years. He has been focusing mainly on spotting long term value investments in biotechnology, pharmaceutical, health insurance, hospital, and medical device sectors.
"One of the best ways to do well in this business is to go to areas that have been unexploited by research capability and work them for all you can." -Julian Robertson
Bram de Haas lives with his girlfriend and baby son in The Netherlands/Nijmegen. Living in a city once a Roman settlement later bombed by allied forces in WO II he is aware of the vulnerability of Empires and the impact of the unexpected.
His investment style can be summed up as safety first. Once safe: be agressive.
Value & Momentum Breakouts. If targeting 5% weekly or monthly returns is more appealing to you than chasing 5% annually, please join me as I publish my latest findings in weekly and monthly articles! During my more than 25 years of investing I got bored with low annual returns and began looking to harness well documented financial anomalies for excess risk adjusted returns. I leverage forensic analysis and the latest academic financial models to identify profitable irregularities in fundamental and momentum characteristics. I am a finance PhD and MBA who is always looking for new investments and profitable opportunities in an ever changing market. I am also a certified fraud examiner and investment adviser who thoroughly enjoys testing new financial theories.
BIO: Vincent Tizono is a financial analyst and private speculator. He graduated summa cum laude with a Bachelor of Science from Rocky Mountain College. He's a former Edward Jones Financial Advisor who worked at Edward Jones Headquarters in St. Louis, Missouri, handling multiple offices in transition. The cumulative assets under management for the 11 advisor team totaled over $400 million. Furthermore, Vincent was apart of the FACD program at Edward Jones, which only 1 in 500 applicants are accepted into.
I have a unique talent for finding high-quality speculations and catalyst plays in the biotech space. My last six speculations were ZSAN, FLXN, CPRX, VSTM, OCUL, and AUPH. I wrote articles outlining each of these opportunities; except for ZSAN and FLXN which were just blog posts stating that they were currently worth buying as speculations. All four articles and the two blog posts can be found under my profile.
ZSAN--22% in 5 days (the write up is in my Sep 30th Biotech Brief)
FLXN--21% in 65 days
CPRX--26% in 5 days
VSTM--24% in 3 days
OCUL--14% in 5 days
AUPH--42% in 6 days
--Returns have been calculated by assuming that a position was taken on the open of the day that the piece was published and sold on the close of the day that it hit my stated price target or, in the absence of that, the day before the data readout.
The results of my Long-term oriented articles:
CARA: The stock ran up 86% between the time of my first article and my second article. Also, I explained in my second article that I thought it was smart to lock in profits and thus reduced my position to only 25% of my original position.
AIMT: The stock is currently up a little over 69% since my first article.
GWPH: -- I didn’t suggest buying at these levels but rather I explained why I am still holding long even though I, at that point, was up 188% (I included a pic of my brokerage account since 188% is such a stellar return and thus a large claim)
TTNP: I articulated why the equity would struggle, and currently the stock is down a little over 50% since my article.
PLX: The stock is down since I wrote about it, but this is the type of little stock that you either make multiples of your money or it will go to zero. Thus, size your position accordingly and check back in a couple of years.
(Long-term is often seen as 5 years + but I focus on the fast-moving and highly volatile industry of small-cap biotech, so I consider long-term as 1 year or more)
My Style: I look for compelling speculations in the small/mid-cap space of the biotech industry. Each speculation has its own nuances and idiosyncratic risks that are associated with it. However, generally speaking, my speculating focuses on finding windows in time when probability favors appreciation, there’s solid visibility on the risks and possible outcomes, and a high reward to risk ratio is present. Furthermore, equity markets manipulate the emotional weaknesses of speculators. Thus, my entries, exists, and sizing of positions are decided on in a systematic fashion. Lastly, I believe that sound bankroll/risk management is the key to profitable speculation. Proper bankroll/risk management is what will allow you to overcome the randomness that is inherent in security speculation by allowing you to handle drawdowns from a negative sequence of returns.
Wisdom: “No man so wise that he may not easily err if he takes no other counsel than his own. He that is taught only by himself has a fool for a master”-Ben Johnson
"There is nothing so disastrous as a rational investment policy in an irrational world"-John Maynard Keynes
"Amateurs care about how much they can make, but professionals care about how much they can lose"
RagingBull.com is the premier destination for both new or experienced active traders who are looking for stock picks, stock ideas, how to get started trading stocks, and overall stock market education. Our team is comprised of real millionaire stock traders who put their money to work every day in the markets by actively trading penny stocks, ETF’s, options, small-cap stocks and biotech stocks.